BIO

Allison Moser has been a nurse practitioner for 10 years, with the past 7 years dedicated to specializing in hepatology. She currently serves as the Lead Advanced Practice Provider of Solid Organ Transplant at Rush University Medical Center in Chicago, IL. She has been a member of the Illinois Board of Directors for the American Liver Foundation (ALF) and has co-chaired the Associate Medical Advisory Committee (AMAC). Additionally, she serves as faculty for Gastroenterology & Hepatology Advanced Practice Providers (GHAPP) and is a member of the American Association for the Study of Liver Diseases (AASLD) Associates Committee.

MASLD-MASH Content Featuring Allison

Webcast: Non-Invasive Testing With Allison Moser

November 2025

In this educational session from the GHAPP MASLD Community Network, Allison Moser, NP, from Rush University Medical Center, explains how non-invasive testing (NITs) is changing the way clinicians assess and manage metabolic-associated steatotic liver disease (MASLD) and metabolic-associated steatohepatitis (MASH). Through a real patient case study, she reviews key diagnostic tools like FIB-4, ELF, FibroScan, and MRI elastography, highlighting how each test helps identify fibrosis risk, reduce the need for biopsy, and guide patient management. Learn how to interpret test results, understand their limitations, and apply them in everyday clinical practice to improve liver health outcomes. #MASLD #MASH #Fibrosis #NonInvasiveTesting #FIB4 #ELFTest #FibroScan #MRIelastography #LiverHealth #Hepatology #APPeducation

Watch Now arrow

Webcast: MASLD Pharmacotherapy With Allison Moser

November 2025

Join Allison Moser, NP, hepatology nurse practitioner at Rush University Medical Center, for a comprehensive update on pharmacotherapy in MASLD and MASH. In this MASLD Community Network session, Allison reviews the evolving treatment landscape—from lifestyle and metabolic management to the latest FDA-approved medications. Learn how resmetirom, the first and only approved therapy for MASH with stage 2–3 fibrosis, works as a thyroid hormone receptor-β agonist to improve liver fat and fibrosis. Discover the growing role of GLP-1 receptor agonists such as semaglutide in MASH management, as well as key insights on vitamin E, pioglitazone, and metabolic risk reduction through diet, exercise, and comorbidity control. This evidence-based discussion highlights the latest clinical trial data, practice guidelines, and real-world considerations for advanced practice providers managing metabolic liver disease. #MASH #MASLD #LiverHealth #Hepatology #APPeducation #Resmetirom #Semaglutide #FattyLiverDisease #NASH #MetabolicHealth

Watch Now arrow

Diet and Nutrition: Tailoring Plans for Diverse Populations

October 2025

In this episode, Allison Moser, NP, from Rush University Medical Center, dives into one of the most impactful aspects of MASH (Metabolic Dysfunction–Associated Steatohepatitis) management — diet and nutrition. While weight loss is often the starting point, Allison explains why sustainable liver health depends on personalized, culturally sensitive, and practical nutrition strategies. Learn how evidence-based eating patterns like the Mediterranean diet and plant-based diets can reduce hepatic steatosis, improve insulin sensitivity, and lower inflammation, even without weight loss. Allison shares actionable food swaps for diverse cultures, affordable ways to eat healthy when access is limited, and tailored recommendations for patients with comorbidities like diabetes, CKD, and cardiovascular disease. She also discusses the major role of added sugars, processed foods, and sugary or diet beverages in driving liver damage — and how to help patients make realistic, stepwise changes that last. Whether you’re an APP, NP, PA, or clinician treating patients with MASH or MASLD, this episode offers practical, evidence-based tools to improve nutrition counseling, build patient trust, and support long-term liver health.

Watch Now arrow

Common Questions From Primary Care Providers About MASH With Allison Moser

September 2025

In this quick and practical episode, Allison Moser, a hepatology nurse practitioner at Rush University Medical Center in Chicago, answers three of the most common patient questions about metabolic dysfunction–associated steatohepatitis (MASH). She explains how MASH differs from MASLD (fatty liver disease without damage), why it develops in people who don’t drink alcohol, and how it can be reversed with lifestyle changes and new FDA-approved therapies. Allison highlights the link between MASH and metabolic syndrome conditions such as type 2 diabetes, obesity, high cholesterol, and hypertension, underscoring the importance of early identification and treatment. She also discusses the effectiveness of weight loss, dietary approaches like the Mediterranean diet, physical activity, and emerging pharmacologic therapies including resmetirom and semaglutide for patients with stage 2–3 fibrosis. Designed to keep the message simple and patient-centered, this video offers guidance for patients, families, and providers who want to better understand MASH, its risks, and how early action can reverse liver damage and prevent progression to cirrhosis.

Watch Now arrow

Management of Lifestyle Modification

January 2025

This video focuses on the comprehensive management of patients with metabolic-associated steatohepatitis (MASH), emphasizing lifestyle modifications, dietary adjustments, and exercise strategies. Key topics include the importance of addressing risk factors like diet, exercise habits, and alcohol intake, as well as referrals to medically supervised weight loss clinics or bariatric surgery for advanced cases. The speaker highlights the benefits of the Mediterranean diet, intermittent fasting, and avoiding ultra-processed foods while discussing the role of resistance training to combat sarcopenia and maintain muscle mass. Practical advice and tailored recommendations ensure a holistic approach to managing MASH and improving patient outcomes.

Watch Now arrow

Third Step of Lifestyle Management

January 2025

This video provides a comprehensive overview of emerging pharmacologic treatments for metabolic-associated steatohepatitis (MASH) and their tailored applications based on patient profiles. Topics include FDA-approved therapies, drugs in advanced clinical trials (such as semaglutide and lanifibranor), and the potential for combination treatments targeting both steatohepatitis and fibrosis. The speaker emphasizes the importance of patient-specific approaches considering metabolic profiles, obesity, and diabetes status, alongside lifestyle interventions. Additionally, the video discusses the evolving interdisciplinary care model and highlights the exciting progress in non-invasive testing and treatment advancements for F2-F3 fibrosis.

Watch Now arrow

Approved Medication for MASH/NASH

January 2025

This video provides detailed guidance on selecting and monitoring patients for emerging therapies targeting advanced fibrosis (F2-F3) in NASH. Key topics include contraindications for patients with cirrhosis, considerations for concomitant medications, and dose adjustments for statins. The video outlines ideal candidates based on specific thresholds for VCTE, MRE, ELF scores, and other non-invasive tests while emphasizing the importance of ruling out portal hypertension and other liver diseases. It also reviews a stepwise monitoring approach, focusing on tolerability at three months and efficacy assessments at six and twelve months, with an emphasis on histologic and non-invasive test improvements.

Watch Now arrow

Types of Diet for the Treatment of MASLD

January 2025

This video explores comprehensive strategies for managing metabolic-associated steatohepatitis (MASH), focusing on fibrosis risk stratification, lifestyle modifications, and pharmacologic interventions. Learn about dietary recommendations like the Mediterranean diet, exercise guidelines emphasizing resistance training, and the role of intermittent fasting and processed food avoidance. The video also highlights weight loss targets, diabetes management, and emerging therapies such as GLP-1 receptor agonists and bariatric surgery, all aimed at improving liver health and patient outcomes.

Watch Now arrow

NITs to Identify High Risk MASH Patients

January 2025

Explore advancements in non-invasive diagnostics and risk stratification for liver fibrosis and MASH. This video highlights tools like FIB-4, transient elastography, and innovative scoring systems (e.g., FAST and Agile) to identify and predict outcomes for high-risk patients. Learn about serum biomarkers, updated guidelines, and the role of lifestyle interventions alongside targeted therapies for managing metabolic risks and advancing care in hepatology.

Watch Now arrow
View All arrow arrow

Click the arrows to view more content

Highlighted Events

Breakthroughs in MASH Diagnosis & Management

December 02 @ 06:30 pm - 09:30 pm EST

Register to join us at a Liver Connect City Series Event, Breakthroughs in MASH Diagnosis & Management with speakers Naim Alkhouri, MD, FAASLD, Pi..

Breakthroughs in MASH Diagnosis & Management

January 13 @ 06:30 pm - 09:30 pm CST

Register to join us at a Liver Connect City Series Event, Breakthroughs in MASH Diagnosis & Management with Bradley Freilich, MD, AGAF, Steven Fla..

Breakthroughs in MASH Diagnosis & Management

March 11 @ 06:30 pm - 09:30 pm CDT

Register to join us at a Liver Connect City Series Event, Breakthroughs in MASH Diagnosis & Management with Nancy Reau, MD, Sujit Janardhan, MD, P..

Breakthroughs in MASH Diagnosis & Management

March 26 @ 06:30 pm - 09:30 pm EST

Register to join us at a Liver Connect City Series Event, Breakthroughs in MASH Diagnosis & Management with Kimberly Brown, MD, Robert Fontana, MD..

View All arrow arrow

Related Content

Clinical Deep Dive: Unlocking the Treatment Potential of Rezdiffra

March 2025

This educational discussion dives into Rezdiffra, the first and only FDA-approved therapy for non-cirrhotic metabolic-associated steatohepatitis (MASH) with moderate to advanced fibrosis. The talk provides a clinical deep dive into the progression of MASH and fibrosis, highlighting the risks of untreated disease and the importance of early intervention. A key focus is the thyroid hormone receptor beta mechanism, explaining how Rezdiffra directly targets liver-specific pathways to reduce hepatic fat accumulation and fibrosis. Additionally, the discussion covers the rigorous FDA approval process and dual efficacy endpoints, detailing how Rezdiffra achieved significant fibrosis improvement and steatohepatitis resolution in the MAESTRO-NASH trial. The session also provides practical insights into patient access, prescribing considerations, and managing common side effects. With over 2,000 patients studied, Rezdiffra has demonstrated a strong safety profile and offers a once-daily oral treatment option that represents a major advancement in MASH management. This discussion is essential for gastroenterologists, hepatologists, and endocrinologists managing patients with MASH, as well as primary care providers and cardiologists who play a role in identifying at-risk individuals. If you are a healthcare professional looking to stay updated on the latest MASH research and treatment strategies, this session provides the insights you need.

Watch Now arrow

Liver Model Overview

July 2025

Join Alison Moe, PA-C with United Digestive, as she walks through a hands-on demonstration using a life-sized liver model to help patients better understand fibrosis and liver disease progression. In this engaging and practical overview, Allison explains how different stages of liver fibrosis—from normal liver to cirrhosis and hepatocellular carcinoma—can be felt and visualized using a segmented anatomical model. She shares how this tool enhances patient education during discussions about non-invasive liver testing, such as FibroScan, CAP scores, FIB-4, ELF testing, and more. Designed to support visual learners and improve comprehension of disease state, this video is a valuable resource for clinicians and patients navigating the complexities of metabolic-associated fatty liver disease (MASLD) and its progression to MASH. Learn how tactile and visual teaching aids can bridge the gap between diagnostics and patient understanding in hepatology care.

Watch Now arrow

Differentiating Between F3 and F4

July 2025

In this comprehensive discussion, HoChong Gilles, a nurse practitioner with 25 years of hepatology experience at the Richmond VA Medical Center, explores the critical importance of accurately distinguishing between F3 (advanced fibrosis) and F4 (cirrhosis) in patients with MASH (metabolic-associated steatohepatitis). While both stages carry increased risks of liver-specific and overall mortality, Gilles explains that F3 may still be reversible with lifestyle changes or pharmacotherapy, whereas F4 signals irreversible liver damage with heightened risk of complications like portal hypertension, hepatic encephalopathy, and liver cancer. Viewers will gain a deeper understanding of how non-invasive tests—like FIB-4, ELF, FibroScan, and MRE—perform in identifying fibrosis stage, including their limitations and overlaps. Gilles also outlines when to consider liver biopsy, especially in cases with discordant test results, atypical features, or clinical uncertainty. This video emphasizes how staging accuracy informs eligibility for therapies, surveillance strategies like HCC screening, and overall prognosis. Learn how to approach this nuanced distinction in clinical practice and why F3 vs. F4 isn't just semantics—it's a turning point in patient care.

Watch Now arrow

Addressing Health Disparities: Equity Considerations in MASH/MASLD Care

July 2025

In this episode, Patrick Horne, NP at the University of Florida (UF Health), explores the impact of health disparities and socioeconomic inequality on the diagnosis and management of MASH (metabolic-associated steatohepatitis) and MASLD (metabolic dysfunction-associated steatotic liver disease). With a focus on rural and underserved populations, Patrick discusses how limited access to quality healthcare, healthy food, exercise options, and non-invasive testing (NITs) like FibroScan or MRI elastography can delay diagnosis and worsen outcomes. He shares practical, empathetic strategies for individualizing care, such as using accessible tools like FIB-4 or APRI, promoting low-cost physical activity like walking or swimming, and providing culturally sensitive nutrition advice tailored to financial and geographic realities. Patrick emphasizes the provider’s role as a patient advocate and coach, helping patients navigate barriers and create sustainable lifestyle modifications. This episode offers key insights for clinicians working to close gaps in care and promote equity in liver disease management.

Watch Now arrow

Pharmacotherapy Review

July 2025

Join Christina Hanson, FNP-C, from South Denver Gastroenterology, as she provides an in-depth overview of the current pharmacologic treatment landscape for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH). This expert-led session explores the three cornerstones of MASH management—lifestyle and weight loss interventions, cardiovascular risk reduction, and liver-directed therapy—while highlighting the evolving role of GLP-1 receptor agonists and the recent FDA approval of resmetirom, the first medication indicated for adults with MASH and moderate to advanced fibrosis. Christina also discusses clinical trial data from MAESTRO-NASH, reviews historical agents like vitamin E and pioglitazone, and offers practical guidance on patient selection, safety considerations, and monitoring strategies. Whether you’re a GI provider, hepatology specialist, or primary care clinician managing fatty liver disease, this video provides valuable insights into how emerging therapies are shaping the future of MASH treatment.

Watch Now arrow
View All arrow arrow

Click the arrows for more videos

Latest News & Blogs

Wegovy® approved in the US for the treatment of MASH

At Aug 20, 2025

Check out the prescribing information here: https://bit.ly/novo-pi-wegovy

Read More arrow